FDA approves Qulipta for prevention of migraine – AbbVie
The FDA has approved Qulipta (atogepant tablets), from AbbVie, for the preventive treatment of episodic migraine in adults. The approval of Qulipta was based on findings from the… read more.
The FDA has approved Qulipta (atogepant tablets), from AbbVie, for the preventive treatment of episodic migraine in adults. The approval of Qulipta was based on findings from the… read more.
Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and schizophrenia. Current treatment options for memory loss are very limited and… read more.
Study finds diet may contribute to cognitive resilience in the elderly. Rush University Medical Center Aging takes a toll on the body and on the mind. For example,… read more.
Migraines are linked to poorer quality sleep in both adults and children, researchers reported on Sept. 22, 2021 in Neurology As background to the new meta-analysis, investigator and… read more.
Meditating just once proves to make a difference Michigan State University If you are forgetful or make mistakes when in a hurry, a new study from Michigan State… read more.
Scientists have long wondered why almost all animals sleep, despite the disadvantages to survival of being unconscious. Now, researchers led by a team from the University of Tsukuba… read more.
Anxiety, addiction, and other psychiatric disorders are often characterized by intense states of what scientists call arousal: The heart races, blood pressure readings rise, breaths shorten, and “bad”… read more.
For millions of people with epilepsy and movement disorders such as Parkinson’s disease, electrical stimulation of the brain already is widening treatment possibilities. In the future, electrical stimulation… read more.
It’s so commonplace we barely give it a second thought, but human brains seem hardwired to see human faces where there are none — in objects as varied… read more.
“Migraine is one of the most common headache disorders, but only about half the people taking medication for it get real relief,” said study author Rohit Bhatia, M.D.,… read more.
Université de Genève One person in 2000 suffers from a microdeletion of chromosome 22 that can lead to the development of psychotic disorders, such as schizophrenia, in adolescence…. read more.
An experimental treatment produced improvements in cognitive function and language in patients with fragile X syndrome, according to study results published on April 29 in Nature Medicine. Fragile X… read more.